Nuvation Bio Inc.
NUVBHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. At a $1.60B market cap, Nuvation Bio Inc. ranks as a small-cap company within healthcare. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Market Cap
$1.60B
Beta
1.62
P/E (TTM)
—
P/E (Fwd)
-304.67
EPS (TTM)
$-0.44
EPS (Fwd)
$-0.01
ROE
-47.8%
ROA
-12.4%
Cash
$661.0M
Total Debt
$416.3M
Free CF
-$112.1M
52W Change
-9.3%
Annual Financials
Cash vs Debt
Where NUVB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NUVB finished 17.50% below its 150-day moving average ($5.43) and 19.13% below its 200-day moving average ($5.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NUVB overbought or oversold?
At the October 20, 2026 close, NUVB's RSI(14) was 14.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $661.0M in cash and $416.3M in debt, NUVB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$112.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -47.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Nuvation Bio Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nuvation Bio Inc.'s trajectory.